The campaign also includes partnerships with other celebrities, including Lance Bass and Retta.
Stock.adobe.com
Dexcom, Inc., launched a new educational campaign for people with diabetes to help provide them with guidance about beginning their healthcare journey.1 The company teamed up with a variety of celebrities, including Nick Jonas, Lance Bass, Retta, and more to promote the campaign. The campaign is based on the results of new data that says that up to 70% of people diagnosed with diabetes don’t know where to begin their health journey. Many of these same respondents also said that diabetes has prevented them pursuing a passion or interest.
In a press release, Dexcom president and chief executive officer Kevin Sayer said, “At Dexcom, we know better health empowers us all, and I believe World Diabetes Day is the perfect time to change the perception of what’s possible. Our community of users, caregivers, and physicians have inspired us—and we hope that by delivering critical health information across our portfolio of leading glucose biosensors we’re able to do the same. As we build on our legacy of pioneering this industry, we’re committed to helping people at any age and any stage of diabetes receive the information and tools they need to discover what they’re made of.”
In the same press release, singer/actor Nick Jonas added, “A diabetes diagnosis can feel isolating. With the right support and tools, like Dexcom biosensing technology, it doesn't have to be. I'm part of a community that's living proof of what people with all types of diabetes can achieve, and this World Diabetes Day, we hope to inspire others around the world to truly discover what they're made of—and embrace their full potential to live beyond their diagnoses."
Dexcom is also involved in the production of glucose monitoring products. The company also recently announced a strategic partnership with OURA, which will combine Dexcom’s glucose biosensor technology with OURA’s Oura Ring and Oura App.2
In a press release, Dexcom executive vice president of strategy and corporate development Matt Dolan said, “Dexcom offers the most accurate glucose biosensing systems on the market that help reveal the impact of daily lifestyle choices on glucose levels and enable our users to make informed decisions about their health and overall well-being. Partnering with ŌURA gives us the opportunity to redefine the category again, integrating data from Dexcom glucose biosensors with the continuous insights and metrics measured by Oura Ring. This powerful combination will attract new shared customers who want to better understand the link between activity, sleep, nutrition, and their glucose.”
In the same press release, Oura chief executive officer Tom Hale added, “Ninety-seven percent of Oura Members have expressed interest in understanding how the food they eat impacts their health. This partnership with Dexcom will enable us to empower our members to make informed decisions and adjust behaviors to positively impact their biometrics and long-term health. Working together, ŌURA and Dexcom will help members decide what and when to eat by surfacing correlations between activities like sleep and exercise and members’ glucose levels. And because we know that people are affected differently by the same foods and activities, guidance and insights will be personalized.”
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.